Chong Kun Dang Pharmaceutical Corp. Logo

Chong Kun Dang Pharmaceutical Corp.

185750 | KO

Overview

Corporate Details

ISIN(s):
KR7185750007
LEI:
Country:
South Korea
Address:
서울 서대문구 충정로3가 3가 368 종근당빌딩, 서대문구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

No description available.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-29 00:00
Regulatory Filings
투자판단관련주요경영사항 (텔미누보정(CKD828) 식품의약품안전처 국내 품목허가 승인)
Korean 7.2 KB
2025-08-22 00:00
Regulatory Filings
투자판단관련주요경영사항 (텔미누보정(CKD828) 식품의약품안전처 국내 품목허가 신청)
Korean 13.5 KB
2025-08-14 00:00
Interim / Quarterly Report
반기보고서 (2025.06)
Korean 4.9 MB
2025-08-01 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 13.3 KB
2025-07-24 00:00
Governance Information
공정거래자율준수프로그램운영현황(안내공시)
Korean 15.8 KB
2025-06-24 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 99.9 KB
2025-06-12 00:00
Regulatory Filings
유형자산취득결정
Korean 7.9 KB
2025-06-12 00:00
Regulatory Filings
풍문또는보도에대한해명(미확정)
Korean 8.0 KB
2025-06-10 00:00
Regulatory Filings
풍문또는보도에대한해명(미확정)
Korean 6.2 KB
2025-06-02 00:00
Governance Information
기업지배구조보고서공시
Korean 1.8 MB
2025-05-22 00:00
Regulatory Filings
기타경영사항(자율공시) (CKD510 기술수출 관련 마일스톤 수령)
Korean 5.2 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 2.9 MB
2025-04-30 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 13.3 KB
2025-04-23 00:00
Regulatory Filings
투자판단관련주요경영사항 (듀비엠폴서방정(CKD383) 식품의약품안전처 국내 품목허가 신청)
Korean 16.9 KB
2025-04-23 00:00
Regulatory Filings
투자판단관련주요경영사항 (듀비엠파정(CKD398) 식품의약품안전처 국내 품목허가 신청)
Korean 16.6 KB

Automate Your Workflow. Get a real-time feed of all Chong Kun Dang Pharmaceutical Corp. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Chong Kun Dang Pharmaceutical Corp.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Chong Kun Dang Pharmaceutical Corp. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

A global CDEMO offering end-to-end solutions for antibody therapeutics and biologics.
South Korea
334970
Develops affordable biosimilars and novel antibody drugs for life-threatening diseases.
Singapore
950210
Prestige Consumer Healthcare Inc. Logo
Develops and markets leading over-the-counter brands for personal healthcare and wellness.
United States of America
PBH
Prime Medicine, Inc. Logo
Developing 'search and replace' gene editing therapies to treat genetic disorders.
United States of America
PRME
Probi Logo
Develops and manufactures clinically proven probiotics for B2B supplement & nutrition partners.
Sweden
PROB
Develops scientifically validated probiotics for cardiometabolic health for consumers & partners.
United Kingdom
PBX
Processa Pharmaceuticals, Inc. Logo
Develops next-gen chemo and therapies for chronic and life-threatening diseases.
United States of America
PCSA
Develops protein-based immunotherapies for metabolic diseases, immune disorders, and cancer.
South Korea
296160
PROKIDNEY CORP. Logo
Develops cellular therapies to preserve kidney function for patients with advanced Chronic Kidney Disease.
United States of America
PROK
ProPhase Labs, Inc. Logo
Genomics, diagnostics, contract manufacturing, and OTC health & wellness solutions provider.
United States of America
PRPH

Talk to a Data Expert

Have a question? We'll get back to you promptly.